Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

Shire CEO thinks he can beat $500M in postmerger cost savings

Emily Wasserman Shire may have clinched its $ 32 billion deal to buy Baxalta, but not everyone is breaking out the confetti. Some analysts aren't sold on the tie-up, saying they ...

Single-minded Shire finally pins down Baxalta with $32B deal

Carly Helfand The new year has its first megadeal agreement, thanks to Shire and Baxalta. On Monday, the two finally announced a $ 32 billion tie-up after a months-long pursuit by ...

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

John Carroll It took a few months, but Shire has wrapped a $ 32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors. FierceBiotech ...

Shire inches closer to Baxalta buy with cash-sweetened bid

Carly Helfand Shire has offered up a new bid for elusive target Baxalta that's more or less what the Illinois drugmaker has been looking for, reports say. But that doesn't ...

Shire prepared to walk on Baxalta talks if deal doesn’t come soon: WSJ

Carly Helfand Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to ...

Shire and longtime target Baxalta meeting to talk takeover: Bloomberg

Carly Helfand Shire has refused to give up on target Baxalta, which first rejected it 5 months ago. And its persistence may finally be paying off. FiercePharma News

Shire and Sangamo break up their gene-editing partnership

Damian Garde Shire and Sangamo Biosciences are going their separate ways after three-plus years of collaboration in gene editing, with each company hanging on to the programs best aligned ...

Shire raise its $30B Baxalta bid? It’s going to need some details first

Carly Helfand Earlier this week, Baxalta CEO Ludwig Hantson called Shire's $ 30 billion bid for his company a "lowball" offer, urging shareholders instead to look to ...

Shire might dial up its $30B Baxalta offer, but not without more info

Alok Saboo Shire may consider upping its pitch for Baxalta, but first it needs more details on the financial future of its target. FierceBiotech News

Baxalta to Shire: We’re young, we’re just starting to grow, and we’re rejecting your buyout offer

Carly Helfand On Tuesday, Shire went public with a $ 30 billion bid for Baxalta that had already been rejected once. And the second time around, Baxalta had the same answer: It's ...
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS